Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Cervical Cancer

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 158 articles: HTML format

Single Articles

August 2021
1. SALTA S, Maia-Moco L, Estevao-Pereira H, Sequeira JP, et al
   Performance of DNA methylation-based biomarkers in the Cervical Cancer Screening Program of Northern Portugal: a feasibility study.
   Int J Cancer. 2021 Aug 30. doi: 10.1002/ijc.33778.
   PubMed     Abstract available
   
   
   
2. KEANE A, Ng CW, Simms KT, Nguyen D, et al
   The road to cervical cancer elimination in Malaysia: Evaluation of the impact and cost-effectiveness of HPV screening with self-collection and digital registry support.
   Int J Cancer. 2021 Aug 7. doi: 10.1002/ijc.33759.
   PubMed     Abstract available
   
   
   June 2021
3. VAN SCHALKWYK C, Moodley J, Welte A, Johnson LF, et al
   Modelling the impact of prevention strategies on cervical cancer incidence in South Africa.
   Int J Cancer. 2021 Jun 24. doi: 10.1002/ijc.33716.
   PubMed     Abstract available
   
   
   
4. BUDUKH A, Dikshit R, Chaturvedi P
   Outcome of the randomized control screening trials on Oral, Cervix and Breast Cancer from India and way forward in COVID-19 pandemic situation.
   Int J Cancer. 2021 Jun 21. doi: 10.1002/ijc.33712.
   PubMed    
   
   
   
5. JAYARAJ R, Shaw P, Kumarasamy C, Shetty SS, et al
   Comments on "Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis".
   Int J Cancer. 2021;148:2857-2858.
   PubMed    
   
   
   
6. MALAGON T, Volesky KD, Franco EL
   Reply to: Comments on cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis.
   Int J Cancer. 2021;148:2859-2860.
   PubMed    
   
   
   May 2021
7. DEREJE N, Addissie A, Worku A, Gebremariam A, et al
   Association between waiting time for radiotherapy initiation and disease progression among women with cervical cancer in Addis Ababa, Ethiopia.
   Int J Cancer. 2021 May 17. doi: 10.1002/ijc.33689.
   PubMed     Abstract available
   
   
   
8. KITAZAWA S, Takaoka Y, Ueda Y, Kitazawa R, et al
   Identification of Calmodulin-Like Protein 5 (CALML5) as tumor-suppressor gene silenced during early stage of carcinogenesis in squamous cell carcinoma of uterine cervix.
   Int J Cancer. 2021 May 17. doi: 10.1002/ijc.33687.
   PubMed     Abstract available
   
   
   April 2021
9. RAMACHANDRAN D, Wang Y, Schurmann P, Hulse F, et al
   Association of genomic variants at PAX8 and PBX2 with cervical cancer risk.
   Int J Cancer. 2021 Apr 27. doi: 10.1002/ijc.33614.
   PubMed     Abstract available
   
   
   
10. GREEN LI, Mathews CS, Waller J, Kitchener H, et al
    Attendance at early recall and colposcopy in routine cervical screening with human papillomavirus testing.
    Int J Cancer. 2021;148:1850-1857.
    PubMed     Abstract available
    
    
    
11. HOPPE-SEYLER K, Herrmann AL, Daschle A, Kuhn BJ, et al
    Effects of Metformin on the virus/host cell crosstalk in HPV-positive cancer cells.
    Int J Cancer. 2021 Apr 12. doi: 10.1002/ijc.33594.
    PubMed    
    
    
    
12. BORGFELDT C, Soderlund-Strand A, Darlin Flygh L, Forslund O, et al
    HPV73 in cervical cancer and distribution of HPV73 variants in cervical dysplasia.
    Int J Cancer. 2021 Apr 9. doi: 10.1002/ijc.33590.
    PubMed     Abstract available
    
    
    
13. IVERSEN L, Fielding S, Lidegaard O, Hannaford PC, et al
    Contemporary hormonal contraception and cervical cancer in women of reproductive age.
    Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33585.
    PubMed     Abstract available
    
    
    
14. PARRA SG, Lopez-Orellana LM, Molina Duque AR, Carns JL, et al
    Reply to: Comments on Cervical cancer prevention in El Salvador: A prospective evaluation of screening and triage strategies incorporating high-resolution microendoscopy to detect cervical precancer.
    Int J Cancer. 2021 Apr 4. doi: 10.1002/ijc.33586.
    PubMed    
    
    
    
15. PRETORIUS RG, Belinson JL
    COMMENTS ON: CERVICAL CANCER PREVENTION IN EL SALVADOR: A PROSPECTIVE EVALUATION OF SCREENING AND TRIAGE STRATEGIES INCORPORATING HIGH-RESOLUTION MICROENDOSCOPY TO DETECT CERVICAL PRECANCER.
    Int J Cancer. 2021 Apr 4. doi: 10.1002/ijc.33587.
    PubMed    
    
    
    
16. LI N, Hu Y, Zhang X, Liu Y, et al
    DNA methylation markers as triage test for the early identification of cervical lesions in a Chinese population.
    Int J Cancer. 2021;148:1768-1777.
    PubMed     Abstract available
    
    
    March 2021
17. VINK FJ, Dick S, Heideman DAM, De Strooper LMA, et al
    Classification of high-grade CIN by p16(ink4a) , Ki-67, HPV E4 and FAM19A4/miR124-2 methylation status demonstrates considerable heterogeneity with potential consequences for management.
    Int J Cancer. 2021 Mar 17. doi: 10.1002/ijc.33566.
    PubMed     Abstract available
    
    
    
18. ZHAO XL, Liu ZH, Zhao S, Hu SY, et al
    Efficacy of point-of-care thermal ablation among high-risk human papillomavirus positive women in China.
    Int J Cancer. 2021;148:1419-1427.
    PubMed     Abstract available
    
    
    
19. CHINULA L, Topazian HM, Mapanje C, Varela A, et al
    Uptake and safety of community-based 'screen-and-treat' with thermal ablation preventive therapy for cervical cancer prevention in rural Lilongwe, Malawi.
    Int J Cancer. 2021 Mar 9. doi: 10.1002/ijc.33549.
    PubMed     Abstract available
    
    
    February 2021
20. HALL MT, Smith MA, Simms KT, Barnabas R, et al
    Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic HIV infection and active HIV control.
    Int J Cancer. 2021 Feb 26. doi: 10.1002/ijc.33533.
    PubMed     Abstract available
    
    
    
21. HORTLUND M, van Mol T, Van de Pol F, Bogers JP, et al
    Human Papillomavirus Load and Genotype Analysis Improves the Prediction of Invasive Cervical Cancer.
    Int J Cancer. 2021 Feb 14. doi: 10.1002/ijc.33519.
    PubMed     Abstract available
    
    
    
22. DONKEN R, van Niekerk D, Hamm J, Spinelli JJ, et al
    Declining Rates of Cervical Intraepithelial Neoplasia in British Columbia, Canada: An Ecological Analysis On The Effects of The School-Based HPV Vaccination Program.
    Int J Cancer. 2021 Feb 14. doi: 10.1002/ijc.33513.
    PubMed    
    
    
    
23. HUANG HJ, Tung HJ, Yang LY, Chao A, et al
    Role of human papillomavirus status after conization for high-grade cervical intraepithelial neoplasia.
    Int J Cancer. 2021;148:665-672.
    PubMed     Abstract available
    
    
    January 2021
24. EL-ZEIN M, Gotlieb W, Gilbert L, Hemmings R, et al
    Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
    Int J Cancer. 2021;148:492-501.
    PubMed     Abstract available
    
    
    
25. INTURRISI F, Lissenberg-Witte BI, Veldhuijzen NJ, Bogaards JA, et al
    Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer.
    Int J Cancer. 2021;148:320-328.
    PubMed     Abstract available
    
    
    December 2020
26. PARRA SG, Lopez-Orellana LM, Molina Duque AR, Carns JL, et al
    Cervical cancer prevention in El Salvador: A prospective evaluation of screening and triage strategies incorporating high-resolution microendoscopy to detect cervical precancer.
    Int J Cancer. 2020 Dec 24. doi: 10.1002/ijc.33454.
    PubMed     Abstract available
    
    
    November 2020
27. LU Z, Zhu M, Marley JL, Bi K, et al
    The combined action of Mo-MDSCs and MAIT cells promotes the progression of cervical cancer.
    Int J Cancer. 2020 Nov 27. doi: 10.1002/ijc.33411.
    PubMed     Abstract available
    
    
    
28. MALAGON T, Volesky KD, Bouten S, Laprise C, et al
    Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis.
    Int J Cancer. 2020;147:2695-2707.
    PubMed     Abstract available
    
    
    
29. PINHEIRO M, Gage JC, Clifford GM, Demarco M, et al
    Association of HPV35 with cervical carcinogenesis among women of African ancestry: Evidence of viral-host interaction with implications for disease intervention.
    Int J Cancer. 2020;147:2677-2686.
    PubMed     Abstract available
    
    
    
30. BIZZARRI N, Anchora LP, Cattani P, De Vincenzo R, et al
    Peritoneal Hpv-Dna Test In Cervical Cancer (Pioneer Study): A Proof Of Concept.
    Int J Cancer. 2020 Nov 5. doi: 10.1002/ijc.33380.
    PubMed     Abstract available
    
    
    
31. XUE Z, Novetsky AP, Einstein MH, Marcus JZ, et al
    A demonstration of automated visual evaluation of cervical images taken with a smartphone camera.
    Int J Cancer. 2020;147:2416-2423.
    PubMed     Abstract available
    
    
    October 2020
32. TIAN X, Ge D, Zhang F, Zhang B, et al
    Dynamic analysis of circulating tumor DNA to predict prognosis and monitor therapeutic response in metastatic relapsed cervical cancer.
    Int J Cancer. 2020 Oct 28. doi: 10.1002/ijc.33362.
    PubMed     Abstract available
    
    
    
33. REZHAKE R, Chen F, Hu SY, Zhao XL, et al
    Triage options to manage high-risk human papillomavirus-positive women: A population-based cross-sectional study from rural China.
    Int J Cancer. 2020;147:2053-2064.
    PubMed     Abstract available
    
    
    
34. RAMIREZ AT, Sanchez GI, Nedjai B, Agudelo MC, et al
    Effective methylation triage of HPV positive women with abnormal cytology in a middle-income country.
    Int J Cancer. 2020 Oct 2. doi: 10.1002/ijc.33314.
    PubMed     Abstract available
    
    
    
35. CUZICK J, Adcock R, Carozzi F, Gillio-Tos A, et al
    Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening.
    Int J Cancer. 2020;147:1864-1873.
    PubMed     Abstract available
    
    
    September 2020
36. BONDE J, Floore A, Ejegod D, Vink FJ, et al
    Methylation markers FAM19A4 and miR124-2 as triage strategy for primary HPV screen positive women; A large European multi-center study.
    Int J Cancer. 2020 Sep 30. doi: 10.1002/ijc.33320.
    PubMed     Abstract available
    
    
    
37. EL-ZEIN M, Cheishvili D, Gotlieb W, Gilbert L, et al
    Genome-wide DNA methylation profiling identifies two novel genes in cervical neoplasia.
    Int J Cancer. 2020;147:1264-1274.
    PubMed     Abstract available
    
    
    August 2020
38. LOOPIK DL, Ebisch RM, IntHout J, Melchers WJ, et al
    The relative risk of noncervical high-risk human papillomavirus-related (pre)malignancies after recurrent cervical intraepithelial neoplasia grade 3: A population-based study.
    Int J Cancer. 2020;147:897-900.
    PubMed     Abstract available
    
    
    
39. WALPOLE E, Dunn N, Youl P, Harden H, et al
    Nonbreast cancer incidence, treatment received and outcomes: Are there differences in breast screening attendees versus nonattendees?
    Int J Cancer. 2020;147:856-865.
    PubMed     Abstract available
    
    
    July 2020
40. BURGER EA, Portnoy A, Campos NG, Sy S, et al
    Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries.
    Int J Cancer. 2020 Jul 24. doi: 10.1002/ijc.33233.
    PubMed     Abstract available
    
    
    
41. LOUVANTO K, Eriksson T, Gray P, Apter D, et al
    Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women.
    Int J Cancer. 2020;147:440-447.
    PubMed     Abstract available
    
    
    
42. ARBYN M, Gultekin M, Morice P, Nieminen P, et al
    The European response to the WHO call to eliminate cervical cancer as a public health problem.
    Int J Cancer. 2020 Jul 7. doi: 10.1002/ijc.33189.
    PubMed     Abstract available
    
    
    
43. PONTI A, Basu P, Ritchie D, Anttila A, et al
    Key issues that need to be considered while revising the current annex of the European Council Recommendation (2003) on cancer screening.
    Int J Cancer. 2020;147:9-13.
    PubMed     Abstract available
    
    
    June 2020
44. TOTA JE, Isidean SD, Franco EL
    Defining benchmarks for tolerable risk thresholds in cancer screening: Impact of HPV vaccination on the future of cervical cancer screening.
    Int J Cancer. 2020 Jun 25. doi: 10.1002/ijc.33178.
    PubMed     Abstract available
    
    
    
45. RAMACHANDRAN D, Schurmann P, Mao Q, Wang Y, et al
    Association of genomic variants at the Human Leukocyte Antigen locus with cervical cancer risk, HPV status, and gene expression.
    Int J Cancer. 2020 Jun 24. doi: 10.1002/ijc.33171.
    PubMed     Abstract available
    
    
    
46. FARNSWORTH A, Roberts JM, Garland SM, Crescini J, et al
    Detection of high-grade cervical disease among women referred directly to colposcopy following a positive HPV screening test varies with age and cytology findings.
    Int J Cancer. 2020 Jun 2. doi: 10.1002/ijc.33128.
    PubMed     Abstract available
    
    
    May 2020
47. JENKINS D, Molijn A, Kazem S, Pirog EC, et al
    Molecular and pathological basis of HPV-negative cervical adenocarcinoma seen in a global study.
    Int J Cancer. 2020 May 31. doi: 10.1002/ijc.33124.
    PubMed     Abstract available
    
    
    
48. SENGAYI-MUCHENGETI M, Joko-Fru WY, Miranda-Filho A, Egue M, et al
    Cervical cancer survival in sub-Saharan Africa by age, stage at diagnosis and Human Development Index (HDI): A population-based registry study.
    Int J Cancer. 2020 May 25. doi: 10.1002/ijc.33120.
    PubMed     Abstract available
    
    
    
49. LI X, Ding L, Song L, Gao W, et al
    Effects of exposure to polycyclic aromatic hydrocarbons combined with high-risk human papillomavirus infection on cervical intraepithelial neoplasia: A population study in Shanxi Province, China.
    Int J Cancer. 2020;146:2406-2412.
    PubMed     Abstract available
    
    
    April 2020
50. YANG H, Ye S, Goswami S, Li T, et al
    Highly immunosuppressive HLADR(hi) regulatory T cells are associated with unfavorable outcomes in cervical squamous cell carcinoma.
    Int J Cancer. 2020;146:1993-2006.
    PubMed     Abstract available
    
    
    March 2020
51. PILLERON S, Cabasag CJ, Ferlay J, Bray F, et al
    Cervical cancer burden in Latin America and the Caribbean: Where are we?
    Int J Cancer. 2020 Mar 9. doi: 10.1002/ijc.32956.
    PubMed     Abstract available
    
    
    
52. HAMMER A, Demarco M, Campos N, Befano B, et al
    Study of the Risks of CIN3+ detection following multiple rounds of HPV testing: Results of the 15-year cervical cancer screening experience at Kaiser Permanente Northern California.
    Int J Cancer. 2020 Mar 6. doi: 10.1002/ijc.32950.
    PubMed     Abstract available
    
    
    February 2020
53. VENETIANER R, Clarke MA, van der Marel J, Tota J, et al
    Identification of HPV Genotypes Causing Cervical Pre-Cancer using Tissue-Based Genotyping.
    Int J Cancer. 2020 Feb 9. doi: 10.1002/ijc.32919.
    PubMed     Abstract available
    
    
    
54. LIPPENS L, Van Bockstal M, De Jaeghere EA, Tummers P, et al
    Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead towards personalized treatment.
    Int J Cancer. 2020 Feb 3. doi: 10.1002/ijc.32893.
    PubMed     Abstract available
    
    
    January 2020
55. TRICKEY A, May MT, Gill MJ, Grabar S, et al
    Cause-specific mortality after diagnosis of cancer among HIV-positive patients: a collaborative analysis of cohort studies.
    Int J Cancer. 2020 Jan 31. doi: 10.1002/ijc.32895.
    PubMed     Abstract available
    
    
    
56. ZHAO XL, Xu XQ, Duan XZ, Rezhake R, et al
    Comparative performance evaluation of different HPV tests and triaging strategies using self-samples and feasibility assessment of thermal ablation in 'colposcopy and treat' approach: a population-based study in rural China.
    Int J Cancer. 2020 Jan 22. doi: 10.1002/ijc.32881.
    PubMed     Abstract available
    
    
    
57. CHAN K, Liu SS, Wei N, Ngu SF, et al
    Primary HPV testing with cytology versus cytology alone in cervical screening - a prospective randomized controlled trial (RCT) with two rounds of screening in a Chinese population.
    Int J Cancer. 2020 Jan 10. doi: 10.1002/ijc.32861.
    PubMed     Abstract available
    
    
    December 2019
58. GABY S, Eva E, Andreas W, Wilhelm O, et al
    Reducing Overtreatment Associated with Overdiagnosis in Cervical Cancer Screening - A Model-based Benefit-Harm Analysis for Austria.
    Int J Cancer. 2019 Dec 24. doi: 10.1002/ijc.32849.
    PubMed     Abstract available
    
    
    
59. KANN H, Hortlund M, Eklund C, Dillner J, et al
    Human Papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case-control study.
    Int J Cancer. 2019 Dec 23. doi: 10.1002/ijc.32848.
    PubMed     Abstract available
    
    
    
60. LANDY R, Sasieni PD, Mathews C, Wiggins CL, et al
    Impact of screening on cervical cancer incidence. A population-based case-control study in the United States.
    Int J Cancer. 2019 Dec 13. doi: 10.1002/ijc.32826.
    PubMed     Abstract available
    
    
    
61. ELFSTROM KM, Sundstrom K, Andersson S, Bzhalava Z, et al
    Increasing participation in cervical screening by targeting long-term nonattenders: Randomized health services study.
    Int J Cancer. 2019;145:3033-3039.
    PubMed     Abstract available
    
    
    November 2019
62. COSPER PF, McNair C, Gonzalez I, Wong N, et al
    Decreased Local Immune Response and Retained HPV Gene Expression during Chemoradiotherapy are Associated with Treatment Resistance and Death from Cervical Cancer.
    Int J Cancer. 2019 Nov 15. doi: 10.1002/ijc.32793.
    PubMed     Abstract available
    
    
    October 2019
63. SAND FL, Kjaer SK, Frederiksen K, Dehlendorff C, et al
    Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status.
    Int J Cancer. 2019 Oct 24. doi: 10.1002/ijc.32752.
    PubMed     Abstract available
    
    
    
64. FOKOM DOMGUE J, Futuh B, Ngalla C, Kakute P, et al
    Feasibility of a Community-based Cervical Cancer Screening with 'Test and Treat' strategy using self-sample for an HPV Test: Experience from rural Cameroon, Africa.
    Int J Cancer. 2019 Oct 21. doi: 10.1002/ijc.32746.
    PubMed     Abstract available
    
    
    
65. BRAUN JA, Herrmann AL, Blase JI, Frensemeier K, et al
    Effects of the Antifungal Agent Ciclopirox in HPV-Positive Cancer Cells: Repression of Viral E6/E7 Oncogene Expression and Induction of Senescence and Apoptosis.
    Int J Cancer. 2019 Oct 11. doi: 10.1002/ijc.32709.
    PubMed     Abstract available
    
    
    
66. ZORZI M, Del Mistro A, Giorgi Rossi P, Laurino L, et al
    Risk of CIN2 or more severe lesions after negative HPV-mRNA E6/E7 overexpression assay and after negative HPV-DNA test: concurrent cohorts with a 5-year follow up.
    Int J Cancer. 2019 Oct 3. doi: 10.1002/ijc.32695.
    PubMed     Abstract available
    
    
    
67. CASTLE PE, Burk RD, Massad LS, Eltoum IE, et al
    Epidemiological Evidence that Common HPV Types May Be Common Because of Their Ability to Evade Immune Surveillance: Results from the Women's Interagency HIV Study.
    Int J Cancer. 2019 Oct 2. doi: 10.1002/ijc.32693.
    PubMed     Abstract available
    
    
    September 2019
68. SADRI NAHAND J, Moghoofei M, Salmaninejad A, Bahmanpour Z, et al
    Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: A review.
    Int J Cancer. 2019 Sep 30. doi: 10.1002/ijc.32688.
    PubMed     Abstract available
    
    
    
69. STOLER MH, Baker E, Boyle S, Aslam S, et al
    Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology - retrospective insights from ATHENA.
    Int J Cancer. 2019 Sep 6. doi: 10.1002/ijc.32669.
    PubMed     Abstract available
    
    
    August 2019
70. VINK FJ, Meijer CJLM, Clifford GM, Poljak M, et al
    FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study.
    Int J Cancer. 2019 Aug 7. doi: 10.1002/ijc.32614.
    PubMed     Abstract available
    
    
    July 2019
71. TAWE L, MacDuffie E, Narasimhamurthy M, Wang Q, et al
    Human Papillomavirus (HPV) Genotypes in Women with Invasive Cervical Cancer with and without Human Immunodeficiency Virus (HIV) Infection in Botswana.
    Int J Cancer. 2019 Jul 20. doi: 10.1002/ijc.32581.
    PubMed     Abstract available
    
    
    June 2019
72. COLDMAN AJ, van Niekerk D, Krajden M, Smith LW, et al
    Disease Detection at the 48 Month Exit Round of the HPV FOCAL Cervical Cancer Screening Trial in Women Per-Protocol Eligible for Routine Screening.
    Int J Cancer. 2019 Jun 27. doi: 10.1002/ijc.32524.
    PubMed     Abstract available
    
    
    
73. ROHNER E, Butikofer L, Schmidlin K, Sengayi M, et al
    Cervical cancer risk in women living with HIV across four continents: A multicohort study.
    Int J Cancer. 2019 Jun 19. doi: 10.1002/ijc.32260.
    PubMed     Abstract available
    
    
    
74. WOESTENBERG PJ, Bogaards JA, King AJ, Leussink S, et al
    Assessment of herd effects among women and heterosexual men after girls-only HPV16/18 vaccination in the Netherlands: A repeated cross-sectional study.
    Int J Cancer. 2019;144:2718-2727.
    PubMed     Abstract available
    
    
    May 2019
75. WANG J, Elfstrom KM, Andrae B, Nordqvist Kleppe S, et al
    Cervical cancer case-control audit: Results from routine evaluation of a nationwide cervical screening programme.
    Int J Cancer. 2019 May 20. doi: 10.1002/ijc.32416.
    PubMed     Abstract available
    
    
    
76. BAO C, Yang R, Pedersen NL, Xu W, et al
    Overweight in midlife and risk of cancer in late life: A nationwide Swedish twin study.
    Int J Cancer. 2019;144:2128-2134.
    PubMed     Abstract available
    
    
    April 2019
77. AMARO-FILHO SM, Gradissimo A, Usyk M, Moreira FCB, et al
    HPV73 a non-vaccine type causes cervical cancer.
    Int J Cancer. 2019 Apr 9. doi: 10.1002/ijc.32315.
    PubMed     Abstract available
    
    
    March 2019
78. TIAN J, Geng Y, Lv D, Li P, et al
    Using plasma cell free DNA to monitor the chemo-radiotherapy course of cervical cancer.
    Int J Cancer. 2019 Mar 28. doi: 10.1002/ijc.32295.
    PubMed     Abstract available
    
    
    
79. BONDE J, Bottari F, Parvu V, Pedersen H, et al
    BAYESIAN ANALYSIS OF BASELINE RISK OF CIN2 AND >/=CIN3 BY HPV GENOTYPE IN A EUROPEAN REFERRAL COHORT.
    Int J Cancer. 2019 Mar 20. doi: 10.1002/ijc.32291.
    PubMed     Abstract available
    
    
    February 2019
80. VAN LEEUWEN RW, Ostrbenk A, Poljak M, van der Zee AGJ, et al
    DNA methylation markers as a triage test for identification of cervical lesions in a high risk human papillomavirus positive screening cohort.
    Int J Cancer. 2019;144:746-754.
    PubMed     Abstract available
    
    
    January 2019
81. PAN J, Kavanagh K, Cuschieri K, Pollock KG, et al
    Increased risk of HPV-associated genital cancers in men and women as a consequence of pre-invasive disease.
    Int J Cancer. 2019 Jan 16. doi: 10.1002/ijc.32126.
    PubMed     Abstract available
    
    
    
82. LEEMAN A, Del Pino M, Marimon L, Torne A, et al
    Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytology-screened referral population.
    Int J Cancer. 2019;144:160-168.
    PubMed     Abstract available
    
    
    December 2018
83. HAMERS FF, Assogba FAG, Rogel A
    Implementation and organization of cancer screening in France.
    Int J Cancer. 2018;143:3281.
    PubMed    
    
    
    
84. ANDREASSEN T, Hansen BT, Engesaeter B, Hashim D, et al
    Psychological Effect of Cervical Cancer Screening When Changing Primary Screening Method From Cytology to hrHPV testing.
    Int J Cancer. 2018 Dec 14. doi: 10.1002/ijc.32067.
    PubMed     Abstract available
    
    
    
85. SULTANA F, Winch K, Saville M, Brotherton JM, et al
    Is the positive predictive value of high-grade cytology in predicting high-grade cervical disease falling due to HPV vaccination?
    Int J Cancer. 2018 Dec 10. doi: 10.1002/ijc.32050.
    PubMed     Abstract available
    
    
    
86. RADER JS, Tsaih SW, Fullin D, Murray MW, et al
    Genetic variations in human papillomavirus and cervical cancer outcomes.
    Int J Cancer. 2018 Dec 4. doi: 10.1002/ijc.32038.
    PubMed     Abstract available
    
    
    
87. HALEC G, Scott ME, Farhat S, Darragh TM, et al
    Toll-like receptors: Important immune checkpoints in the regression of cervical intra-epithelial neoplasia 2.
    Int J Cancer. 2018;143:2884-2891.
    PubMed     Abstract available
    
    
    November 2018
88. UTADA M, Chernyavskiy P, Lee WJ, Franceschi S, et al
    Increasing risk of uterine cervical cancer among young Japanese women: Comparison of incidence trends in Japan, South Korea and Japanese-Americans between 1985 and 2012.
    Int J Cancer. 2018 Nov 25. doi: 10.1002/ijc.32014.
    PubMed     Abstract available
    
    
    
89. POLMAN NJ, Veldhuijzen NJ, Heideman DAM, Snijders PJF, et al
    Management of HPV-Positive Women in Cervical Screening Using Results from Two Consecutive Screening Rounds.
    Int J Cancer. 2018 Nov 22. doi: 10.1002/ijc.32004.
    PubMed     Abstract available
    
    
    
90. RATAJ O, Haedicke-Jarboui J, Stubenrauch F, Iftner T, et al
    Brd4 inhibition suppresses HPV16 E6 expression and enhances chemoresponse: A potential new target in cervical cancer therapy.
    Int J Cancer. 2018 Nov 13. doi: 10.1002/ijc.31986.
    PubMed     Abstract available
    
    
    
91. COOK DA, Krajden M, Brentnall AR, Gondara L, et al
    Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial.
    Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31976.
    PubMed     Abstract available
    
    
    
92. ISIDEAN SD, Wang Y, Mayrand MH, Ratnam S, et al
    Assessing the Time Dependence of Prognostic Values of Cytology and Human Papillomavirus Testing in Cervical Cancer Screening.
    Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31970.
    PubMed     Abstract available
    
    
    
93. PIMENOFF VN, Tous S, Benavente Y, Alemany L, et al
    Distinct geographic clustering of oncogenic human papillomaviruses multiple infections in cervical cancers: results from a worldwide cross-sectional study.
    Int J Cancer. 2018 Nov 2. doi: 10.1002/ijc.31964.
    PubMed     Abstract available
    
    
    October 2018
94. KAMINENI A, Tiro JA, Beaber EF, Silverberg MJ, et al
    Cervical Cancer Screening Research in the PROSPR I Consortium: Rationale, Methods, and Baseline Findings from a U.S. Cohort.
    Int J Cancer. 2018 Oct 24. doi: 10.1002/ijc.31940.
    PubMed     Abstract available
    
    
    September 2018
95. WANG Q, Song R, Zhao C, Liu H, et al
    HPV16 E6 promotes cervical cancer cell migration and invasion by downregulation of NHERF1.
    Int J Cancer. 2018 Sep 19. doi: 10.1002/ijc.31876.
    PubMed     Abstract available
    
    
    
96. SNOEK BC, Verlaat W, Babion I, Novianti PW, et al
    Genome-wide microRNA analysis of HPV-positive self-samples yields novel triage markers for early detection of cervical cancer.
    Int J Cancer. 2018 Sep 7. doi: 10.1002/ijc.31855.
    PubMed     Abstract available
    
    
    
97. BAUSSANO I, Lazzarato F, Ronco G, Franceschi S, et al
    Impacts of human papillomavirus vaccination for different populations: A modeling study.
    Int J Cancer. 2018;143:1086-1092.
    PubMed     Abstract available
    
    
    August 2018
98. OSTERMAN AL, Winer RL, Gottlieb GS, Sy MP, et al
    Female genital mutilation and non-invasive cervical abnormalities and invasive cervical cancer in Senegal, West Africa: A retrospective study.
    Int J Cancer. 2018 Aug 24. doi: 10.1002/ijc.31829.
    PubMed     Abstract available
    
    
    
99. JOSHI S, Muwonge R, Kulkarni V, Deodhar K, et al
    Incidence of cervical intraepithelial neoplasia in women infected with human immunodeficiency virus (HIV) with no evidence of disease at baseline: results of a prospective cohort study with up to 6.4 years of follow-up from India.
    Int J Cancer. 2018 Aug 22. doi: 10.1002/ijc.31826.
    PubMed     Abstract available
    
    
    
100. CAMPOS NG, Tsu V, Jeronimo J, Regan C, et al
     Health impact of delayed implementation of cervical cancer screening programs in India: A modelling analysis.
     Int J Cancer. 2018 Aug 21. doi: 10.1002/ijc.31823.
     PubMed     Abstract available
     
     
     
101. BUCCHI L, Baldacchini F, Mancini S, Ravaioli A, et al
     Estimating the impact of an organised screening programme on cervical cancer incidence: a 26-year study from northern Italy.
     Int J Cancer. 2018 Aug 18. doi: 10.1002/ijc.31806.
     PubMed     Abstract available
     
     
     
102. GOMIH A, Smith JS, North KE, Hudgens MG, et al
     DNA methylation of imprinted gene control regions in the regression of low-grade cervical lesions.
     Int J Cancer. 2018;143:552-560.
     PubMed     Abstract available
     
     
     May 2018
103. OLORUNFEMI G, Ndlovu N, Masukume G, Chikandiwa A, et al
     Temporal trends in the epidemiology of cervical cancer in South Africa (1994-2012).
     Int J Cancer. 2018 May 22. doi: 10.1002/ijc.31610.
     PubMed     Abstract available
     
     
     April 2018
104. DE STROOPER LMA, Berkhof J, Steenbergen RDM, Lissenberg-Witte BI, et al
     Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up.
     Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31539.
     PubMed     Abstract available
     
     
     March 2018
105. ANNUNZIATA C, Pezzuto F, Greggi S, Ionna F, et al
     Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma.
     Int J Cancer. 2018 Mar 31. doi: 10.1002/ijc.31412.
     PubMed     Abstract available
     
     
     
106. KELLEN E, Benoy I, Vanden Broeck D, Martens P, et al
     A randomized, controlled trial of two strategies of offering the home-based HPV self-sampling test to non- participants in the Flemish cervical cancer screening program.
     Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31391.
     PubMed     Abstract available
     
     
     
107. YU L, Jiang M, Qu P, Wu Z, et al
     Clinical Evaluation of Human Papillomavirus 16/18 Oncoprotein Test for Cervical Cancer Screening and HPV Positive Women Triage.
     Int J Cancer. 2018 Mar 9. doi: 10.1002/ijc.31368.
     PubMed     Abstract available
     
     
     
108. LEHTINEN M, Soderlund-Strand A, Vanska S, Luostarinen T, et al
     Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I).
     Int J Cancer. 2018;142:949-958.
     PubMed     Abstract available
     
     
     February 2018
109. DEL MISTRO A, Adcock R, Carozzi F, Gillio-Tos A, et al
     HPV genotyping for the cross-sectional and longitudinal probability of developing CIN2.
     Int J Cancer. 2018 Feb 17. doi: 10.1002/ijc.31326.
     PubMed     Abstract available
     
     
     
110. RIETBERGEN MM, van Bokhoven AAJD, Lissenberg-Witte BI, Heideman DAM, et al
     Epidemiologic associations of HPV-positive oropharyngeal cancer and (pre)cancerous cervical lesions.
     Int J Cancer. 2018 Feb 14. doi: 10.1002/ijc.31315.
     PubMed     Abstract available
     
     
     
111. LECAVALIER-BARSOUM M, Chaudary N, Han K, Koritzinsky M, et al
     Targeting the CXCL12/CXCR4 Pathway and Myeloid Cells to Improve Radiation Treatment of Locally Advanced Cervical Cancer.
     Int J Cancer. 2018 Feb 8. doi: 10.1002/ijc.31297.
     PubMed     Abstract available
     
     
     January 2018
112. DE KOK IMCM, Korfage IJ, van den Hout WB, Helmerhorst TJM, et al
     Quality of life assumptions determine which cervical cancer screening strategies are cost-effective.
     Int J Cancer. 2018 Jan 19. doi: 10.1002/ijc.31265.
     PubMed     Abstract available
     
     
     
113. BASU P, Ponti A, Anttila A, Ronco G, et al
     Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report.
     Int J Cancer. 2018;142:44-56.
     PubMed     Abstract available
     
     
     December 2017
114. LUOSTARINEN T, Apter D, Dillner J, Eriksson T, et al
     Vaccination protects against invasive HPV-associated cancers.
     Int J Cancer. 2017 Dec 26. doi: 10.1002/ijc.31231.
     PubMed    
     
     
     
115. GULTEKIN M, Zayifoglu Karaca M, Kucukyildiz I, Dundar S, et al
     Initial results of population based cervical cancer screening program using hpv testing in one million turkish women.
     Int J Cancer. 2017 Dec 13. doi: 10.1002/ijc.31212.
     PubMed     Abstract available
     
     
     
116. SAND FL, Frederiksen K, Munk C, Jensen SM, et al
     Long-Term Risk of Cervical Cancer Following Conization of Cervical Intraepithelial Neoplasia Grade 3 - A Danish Nationwide Cohort Study.
     Int J Cancer. 2017 Dec 8. doi: 10.1002/ijc.31202.
     PubMed     Abstract available
     
     
     October 2017
117. MATSUZAKI S, Serada S, Hiramatsu K, Nojima S, et al
     Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.
     Int J Cancer. 2017 Oct 21. doi: 10.1002/ijc.31124.
     PubMed     Abstract available
     
     
     
118. MATSUO K, Shimada M, Yamaguchi S, Kanao H, et al
     Identifying a candidate population for ovarian conservation in young women with clinical stage IB-IIB cervical cancer.
     Int J Cancer. 2017 Oct 4. doi: 10.1002/ijc.31084.
     PubMed     Abstract available
     
     
     
119. PAN R, Zhu M, Yu C, Lv J, et al
     Cancer incidence and mortality: A cohort study in China, 2008-2013.
     Int J Cancer. 2017;141:1315-1323.
     PubMed     Abstract available
     
     
     September 2017
120. ZHANG Q, Dong L, Hu S, Feng R, et al
     Risk stratification and long-term risk prediction of E6 oncoprotein in a prospective screening cohort in China.
     Int J Cancer. 2017;141:1110-1119.
     PubMed     Abstract available
     
     
     August 2017
121. CLARKE MA, Luhn P, Gage JC, Bodelon C, et al
     Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer.
     Int J Cancer. 2017;141:701-710.
     PubMed     Abstract available
     
     
     
122. CHASIMPHA SJD, Parkin DM, Masamba L, Dzamalala CP, et al
     Three-year cancer incidence in Blantyre, Malawi (2008-2010).
     Int J Cancer. 2017;141:694-700.
     PubMed     Abstract available
     
     
     
123. VELENTZIS LS, Caruana M, Simms KT, Lew JB, et al
     How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccina
     Int J Cancer. 2017 Aug 12. doi: 10.1002/ijc.30926.
     PubMed     Abstract available
     
     
     July 2017
124. VACCARELLA S, Laversanne M, Ferlay J, Bray F, et al
     Cervical cancer in Africa, Latin America and the Caribbean, and Asia: Regional inequalities and changing trends.
     Int J Cancer. 2017 Jul 22. doi: 10.1002/ijc.30901.
     PubMed     Abstract available
     
     
     
125. KHAN S, Oosterhuis K, Wunderlich K, Bunnik EM, et al
     Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease.
     Int J Cancer. 2017;141:393-404.
     PubMed     Abstract available
     
     
     
126. BROTHERTON JM, Tabrizi SN, Phillips S, Pyman J, et al
     Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination.
     Int J Cancer. 2017 Jul 5. doi: 10.1002/ijc.30871.
     PubMed     Abstract available
     
     
     
127. MASSAD LS, Hessol NA, Darragh TM, Minkoff H, et al
     Cervical cancer incidence after up to 20 years of observation among women with HIV.
     Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30866.
     PubMed     Abstract available
     
     
     
128. VELDHUIJZEN NJ, Polman NJ, Snijders PJF, Meijer CJLM, et al
     Stratifying HPV-positive women for CIN3+ risk after one and two rounds of HPV-based screening.
     Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30865.
     PubMed     Abstract available
     
     
     June 2017
129. MATSUMOTO K, Yaegashi N, Iwata T, Yamamoto K, et al
     Early impact of the Japanese immunization program implemented before the HPV vaccination crisis.
     Int J Cancer. 2017 Jun 28. doi: 10.1002/ijc.30855.
     PubMed    
     
     
     May 2017
130. MATSUO K, Shimada M, Aoki Y, Sakamoto M, et al
     Comparison of adjuvant therapy for node-positive clinical stage IB-IIB cervical cancer: Systemic chemotherapy versus pelvic irradiation.
     Int J Cancer. 2017 May 19. doi: 10.1002/ijc.30793.
     PubMed     Abstract available
     
     
     
131. LAM JU, Rebolj M, Moller Ejegod D, Pedersen H, et al
     Human papillomavirus self-sampling for screening nonattenders: Opt-in pilot implementation with electronic communication platforms.
     Int J Cancer. 2017;140:2212-2219.
     PubMed     Abstract available
     
     
     
132. AGORASTOS T, Chatzistamatiou K, Moysiadis T, Kaufmann AM, et al
     Human papillomavirus E7 protein detection as a method of triage to colposcopy of HPV positive women, in comparison to genotyping and cytology. Final results of the PIPAVIR study.
     Int J Cancer. 2017 May 3. doi: 10.1002/ijc.30761.
     PubMed    
     
     
     
133. SHEN C, Liu Y, Shi S, Zhang R, et al
     Long-distance interaction of the integrated HPV fragment with MYC gene and 8q24.22 region up-regulating the allele-specific MYC expression in HeLa cells.
     Int J Cancer. 2017 May 3. doi: 10.1002/ijc.30763.
     PubMed     Abstract available
     
     
     
134. NICOLAS-PARRAGA S, Alemany L, de Sanjose S, Bosch FX, et al
     Differential HPV16 variant distribution in squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma.
     Int J Cancer. 2017;140:2092-2100.
     PubMed     Abstract available
     
     
     April 2017
135. ROHNER E, Sengayi M, Goeieman B, Michelow P, et al
     Cervical Cancer Risk and Impact of Pap-based Screening in HIV-positive Women on Antiretroviral Therapy in Johannesburg, South Africa.
     Int J Cancer. 2017 Apr 25. doi: 10.1002/ijc.30749.
     PubMed     Abstract available
     
     
     
136. BALTZER N, Sundstrom K, Nygard JF, Dillner J, et al
     Risk Stratification in Cervical Cancer Screening by Complete Screening History- Applying Bioinformatics to a General Screening Population.
     Int J Cancer. 2017 Apr 6. doi: 10.1002/ijc.30725.
     PubMed     Abstract available
     
     
     
137. DE MARTEL C, Plummer M, Vignat J, Franceschi S, et al
     Worldwide burden of cancer attributable to HPV by site, country and HPV type.
     Int J Cancer. 2017 Apr 1. doi: 10.1002/ijc.30716.
     PubMed     Abstract available
     
     
     March 2017
138. MEZEI AK, Armstrong HL, Pedersen HN, Campos NG, et al
     Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: a systematic review.
     Int J Cancer. 2017 Mar 15. doi: 10.1002/ijc.30695.
     PubMed     Abstract available
     
     
     
139. HO D, Drake TK, Smith-McCune KK, Darragh TM, et al
     Feasibility of clinical detection of cervical dysplasia using angle-resolved low coherence interferometry measurements of depth-resolved nuclear morphology.
     Int J Cancer. 2017;140:1447-1456.
     PubMed     Abstract available
     
     
     
140. DAS GHOSH D, Mukhopadhyay I, Bhattacharya A, Roy Chowdhury R, et al
     Impact of genetic variations and transcriptional alterations of HLA class I genes on cervical cancer pathogenesis.
     Int J Cancer. 2017 Mar 7. doi: 10.1002/ijc.30681.
     PubMed     Abstract available
     
     
     January 2017
141. RODRIGUEZ AC, Avila C, Herrero R, Hildesheim A, et al
     Cervical cancer incidence after screening with HPV, cytology, and visual methods: 18-year follow-up of the Guanacaste cohort.
     Int J Cancer. 2017 Jan 24. doi: 10.1002/ijc.30614.
     PubMed     Abstract available
     
     
     
142. POLMAN NJ, Uijterwaal MH, Witte BI, Berkhof J, et al
     Good performance of p16/ki-67 dual-stained cytology for surveillance of women treated for high-grade CIN.
     Int J Cancer. 2017;140:423-430.
     PubMed     Abstract available
     
     
     
143. MANCINI S, Ravaioli A, Giuliani O, Vattiato R, et al
     Incidence and survival trends of cervical adenocarcinoma in Italy: Cytology screening has become more effective in downstaging the disease but not in detecting its precursors.
     Int J Cancer. 2017;140:247-248.
     PubMed    
     
     
     December 2016
144. CHEN W, Molijn A, Enqi W, Zhang X, et al
     The variable clinicopathological categories and role of human papillomavirus in cervical adenocarcinoma: A hospital based nation-wide multi-center retrospective study across China.
     Int J Cancer. 2016;139:2687-2697.
     PubMed     Abstract available
     
     
     
145. CAMPOS NG, Tsu V, Jeronimo J, Mvundura M, et al
     To Expand Coverage, or Increase Frequency: Quantifying the Tradeoffs between Equity and Efficiency Facing Cervical Cancer Screening Programs in Low-Resource Settings.
     Int J Cancer. 2016 Dec 7. doi: 10.1002/ijc.30551.
     PubMed     Abstract available
     
     
     November 2016
146. KOCSIS A, Takacs T, Jeney C, Schaff Z, et al
     Performance of a New HPV and Biomarker Assay in Management of hrHPV Positive Women: Subanalysis of the Ongoing Multicenter TRACE Clinical Trial (n>6,000) to Evaluate POU4F3 as a Potential Biomarker of Cervical Precancer and Cancer.
     Int J Cancer. 2016 Nov 22. doi: 10.1002/ijc.30534.
     PubMed     Abstract available
     
     
     
147. HABBEMA D, Weinmann S, Arbyn M, Kamineni A, et al
     Harms of Cervical Cancer Screening in the United States and the Netherlands.
     Int J Cancer. 2016 Nov 16. doi: 10.1002/ijc.30524.
     PubMed     Abstract available
     
     
     October 2016
148. WU S, Wang S, Fu Y, Tang W, et al
     A novel mechanism of rs763110 polymorphism contributing to cervical cancer risk by affecting the binding affinity of CEBP/beta and OCT1 complex to chromatin.
     Int J Cancer. 2016 Oct 28. doi: 10.1002/ijc.30490.
     PubMed     Abstract available
     
     
     
149. HOLT HK, Zhang L, Zhao FH, Hu SY, et al
     Evaluation of multiple primary and combination screening strategies in postmenopausal women for detection of cervical cancer in China.
     Int J Cancer. 2016 Oct 11. doi: 10.1002/ijc.30468.
     PubMed     Abstract available
     
     
     
150. SCHIFFMAN M, Yu K, Zuna R, Terence Dunn S, et al
     Proof-of-principle study of a novel cervical screening and triage strategy: computer-analyzed cytology to decide which HPV-positive women are likely to have >/=CIN2.
     Int J Cancer. 2016 Oct 1. doi: 10.1002/ijc.30456.
     PubMed     Abstract available
     
     
     September 2016
151. OGILVIE GS, Krajden M, van Niekerk D, Smith LW, et al
     HPV For Cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid based cytology for cervical cancer.
     Int J Cancer. 2016 Sep 29. doi: 10.1002/ijc.30454.
     PubMed     Abstract available
     
     
     
152. CASTANON A, Landy R, Sasieni PD
     Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix?
     Int J Cancer. 2016;139:1040-5.
     PubMed     Abstract available
     
     
     August 2016
153. SIMMS KT, Smith MA, Lew JB, Kitchener HC, et al
     Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries.
     Int J Cancer. 2016 Aug 19. doi: 10.1002/ijc.30392.
     PubMed     Abstract available
     
     
     
154. CAMPBELL C, Kafwafwa S, Brown H, Walker G, et al
     Use of thermo-coagulation as an alternative treatment modality in a 'screen-and-treat' programme of cervical screening in rural Malawi.
     Int J Cancer. 2016;139:908-15.
     PubMed     Abstract available
     
     
     
155. SCHIFFMAN M, Hyun N, Raine-Bennett TR, Katki H, et al
     A Cohort Study of Cervical Screening Using Partial HPV Typing and Cytology Triage.
     Int J Cancer. 2016 Aug 10. doi: 10.1002/ijc.30375.
     PubMed     Abstract available
     
     
     May 2016
156. CARLANDER C, Wagner P, Svedhem V, Elfgren K, et al
     Impact of immunosuppression and region of birth on risk of cervical intraepithelial neoplasia among migrants living with HIV in Sweden.
     Int J Cancer. 2016 May 13. doi: 10.1002/ijc.30188.
     PubMed     Abstract available
     
     
     March 2016
157. EBISCH RM, de Kuyper-de Ridder GM, Bosgraaf RP, Massuger LF, et al
     The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples.
     Int J Cancer. 2016 Mar 17. doi: 10.1002/ijc.30090.
     PubMed     Abstract available
     
     
     February 2016
158. BROTHERTON JM, Jit M, Gravitt PE, Brisson M, et al
     Eurogin Roadmap 2015: How has HPV knowledge changed our practice: vaccines.
     Int J Cancer. 2016 Feb 24. doi: 10.1002/ijc.30063.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Cervical Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: